Who are Vistagen Therapeutics, Inc.'s main suppliers?

Vistagen Therapeutics, Inc. (VTGN) key suppliers include: Johnson & Johnson, Johnson & Johnson, Eli Lilly and Company, Eli Lilly and Company, ORANY and 1 more. View the full supplier network at chainsifter.com/chain/VTGN.

Who are Vistagen Therapeutics, Inc.'s major customers?

Vistagen Therapeutics, Inc. (VTGN) key customers include: AFFAMED-THERAPEUTICS-INC, FUJI-PHARMA-CO-LTD, Johnson & Johnson, Johnson & Johnson, Eli Lilly and Company and 6 more. View the full customer network at chainsifter.com/chain/VTGN.

What sector is Vistagen Therapeutics, Inc. in?

Vistagen Therapeutics, Inc. (VTGN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Vistagen Therapeutics, Inc. Supplier List (VTGN): 6 Verified Suppliers

6Suppliers

11Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Vistagen Therapeutics, Inc. (VTGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

2Distinct source URLs

6High confidence

0.759Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Vistagen Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
JNJ	Johnson & Johnson	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: ceived from Fuji Pharma a payment of …
LLY	Eli Lilly and Company	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon …
ORANY	ORANY	72%	of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or a…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third …

Vistagen Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
AFFAMED-THERAPEUTICS-INC	AFFAMED-THERAPEUTICS-INC	92%	Sublicense and other revenue consist of revenue recognized under our License and Collaboration Agreement with AffaMed Therapeutics, Inc. ( the Affamed Agreement )
FUJI-PHARMA-CO-LTD	FUJI-PHARMA-CO-LTD	92%	Sublicense and other revenue consist of revenue recognized under our License and Collaboration Agreement with AffaMed Therapeutics, Inc. ( the Affamed Agreement ) and our Exclusive Negotiation Agreem…
JNJ	Johnson & Johnson	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon …
LLY	Eli Lilly and Company	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from LLY grap…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	al of completing its review of 90% of all applications within ten months from the submission receipt date. Such deadlines are referred to as the PDUFA date. The review process and the PDUFA goal date…
EVERINSIGHT-THERAPEUTICS-INC	EVERINSIGHT-THERAPEUTICS-INC	62%	r actual and/or planned adjustments to our operations, the scope and nature of opportunities related to our success or failure in nonclinical and clinical trials, including the development and commer…
NASDAQ-STOCK-MARKET-LLC	NASDAQ-STOCK-MARKET-LLC	62%	iversion of management time and effort and proceedings against us by governmental entities or others. In the U.S., HIPAA, as amended by the Health Information Technology for Economic and Clinical Hea…
PHERIN-PHARMACEUTICALS-INC	PHERIN-PHARMACEUTICALS-INC	62%	he announcement of top-line results from our PALISADE-3 clinical trial. We expect general and administrative expenses to continue to decrease in future periods as a result of these cash preservation …

Vistagen Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VTGN-DEBT-13459	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2017-03-31.
VTGN-DEBT-13458	Warrants outstanding: 9275858	90%	xbrl warrant detail from xbrl 2025-07-31.
VTGN-DEBT	Debt stack $1.4M	90%	Market cache reports total debt of $1.4M.

Vistagen Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vistagen Therapeutics, Inc..

Vistagen Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
VTGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 59 tracked holders.

Vistagen Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
LLY	Eli Lilly and Company	100.00	1	['customer', 'supplier']
JNJ	Johnson & Johnson	100.00	1	['customer', 'supplier']
ORANY	ORANGE	100.00	1	['customer', 'supplier']
BLTE	Belite Bio, Inc	50.00	2
CTNM	Contineum Therapeutics, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
AMZE	Amaze Holdings, Inc.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
ANIK	Anika Therapeutics, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
DAWN	Day One Biopharmaceuticals Inc	50.00	2
AXSM	Axsome Therapeutics, Inc.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
AVBP	ArriVent BioPharma, Inc.	50.00	2
AORT	Artivion, Inc.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CVRX	CVRx, Inc.	50.00	2

Vistagen Therapeutics, Inc. Supply Chain